GE HealthCare Technologies Inc. Common Stock vs Northrop Grumman Corporation — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $69 (market cap $30.93B), while Northrop Grumman Corporation trades at $500 (market cap $70.42B). The key difference: Northrop Grumman Corporation is far larger — about 2.3× GE HealthCare Technologies Inc. Common Stock's market cap, and Northrop Grumman Corporation pays the higher dividend (1.99%). Which is the better fit depends on your goals.
| GEHC | NOC | |
|---|---|---|
Market Cap | $30.93B | $70.42B |
Volume | 5,033,451 | 1,218,886 |
Sector | Health | Industrials |
52-Week High | $88.16 | $768.02 |
52-Week Low | $59.48 | $473.46 |
Enterprise Value | $39.39B | $84.40B |
Dividend Yield | 0.23% | 1.99% |
Typical Hold Time | — | 82 Days |
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Northrop Grumman (NOC) trades at $481.38, down 0.75% with bearish technical signals despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $7.68 exceeding expectations by 13%. Revenue growth remains steady, reaching $41.95B in 2025, while maintaining healthy profitability with 10.48% net margins. Recent news highlights both competitive challenges from Boeing's $20B fighter contract win and positive developments including new defense awards and record backlog.
The investment case balances strong fundamentals against near-term headwinds. Analyst consensus remains bullish with a $595.69 price target (24% upside), though technical indicators suggest caution. Key opportunities include defense budget tailwinds and B-21/Sentinel programs, while risks involve contract competition and execution challenges in major defense programs.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →